These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15358997)

  • 1. The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer.
    Dewilde S; Anderson R
    Med Decis Making; 2004; 24(5):486-92. PubMed ID: 15358997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
    Kim JJ; Leung GM; Woo PP; Goldie SJ
    J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling cost-effectiveness of cervical cancer screening in Hungary.
    Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
    Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
    Anderson R; Haas M; Shanahan M
    Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.
    Kulasingam SL; Myers ER; Lawson HW; McConnell KJ; Kerlikowske K; Melnikow J; Washington AE; Sawaya GF
    Obstet Gynecol; 2006 Feb; 107(2 Pt 1):321-8. PubMed ID: 16449119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
    Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
    Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
    Wong G; Howard K; Webster A; Chapman JR; Craig JC
    Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
    Plunkett BA; Grobman WA
    Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Costs and effects of alternative screening programs against cervical cancer].
    Gyrd-Hansen D; Hølund B; Andersen P
    Ugeskr Laeger; 1996 Aug; 158(35):4912-5. PubMed ID: 8801698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost effectiveness of human papilloma virus testing in cervical cancer screening: a literature review].
    Mejía A; Salas W
    Biomedica; 2008 Mar; 28(1):160-72. PubMed ID: 18645671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.
    Koong SL; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S44-7. PubMed ID: 17227642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
    Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
    J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.
    Suárez E; Smith JS; Bosch FX; Nieminen P; Chen CJ; Torvinen S; Demarteau N; Standaert B
    Vaccine; 2008 Sep; 26 Suppl 5():F29-45. PubMed ID: 18992380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
    Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
    Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ["Cost-effectiveness" of cervical screening].
    Kostova P
    Akush Ginekol (Sofiia); 2007; 46(6):32-4. PubMed ID: 17974169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoscopic screening for gastric cancer.
    Dan YY; So JB; Yeoh KG
    Clin Gastroenterol Hepatol; 2006 Jun; 4(6):709-16. PubMed ID: 16765306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
    Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
    Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.